Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Keep up with ASCRS Annual Meeting coverage with EyeWorld Onsite
➤ Positive topline results from Phase 3 trial for TED drug with new delivery method
➤ FDA expands dosing interval for wet AMD, DME treatment
➤ IDE granted to noninvasive bioelectric stimulation therapy for dry AMD
➤ First patients dosed in Phase 3 corneal cell therapy
➤ TED investigational treatment fails to meet primary endpoint
➤ OTC eye drop recall after FDA enforcement report cites sterility concerns
➤ ASCRS news and events
➤ Positive topline data from Phase 3 study for thyroid eye disease treatment
➤ Controlled U.S. release of outflow restoration platform for glaucoma
➤ New platform established to help bring supportive evidence to interventional glaucoma
➤ Head-to-head Phase 1b study supports investigational anti-VEGF
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ 24-month pivotal data support efficacy of laser treatment for glaucoma
➤ Low-dose atropine drop meets primary, secondary endpoints in new data analysis
➤ Phase 2 topline data for modifier gene therapy for geographic atrophy
➤ Phase 2 data from study evaluating neuropathic corneal pain shows quality of life improvement
➤ New shelf-stable corneal endothelial cell therapy program begins
➤ ASCRS news and events
➤ FDA issues another response letter for dry eye NDA
➤ FDA denies approval for LHON NDA
➤ Commercial launch of epithelium-on crosslinking in the U.S.
➤ Company news
➤ ASCRS news and events
➤ FDA approves new EDOF with limited dysphotopsias
➤ Phase 1/2 12-month data for IOL-based drug delivery system
➤ Topline results from Phase 2a wet AMD study
➤ FDA grants Breakthrough Device Designation to brain implant technology
➤ FDA allows Phase 1/2 trial to begin for investigational cell therapy for familial drusen
➤ ASCRS news and events
➤ First patients dosed in Phase 3 program evaluating sustained drug delivery for DME
➤ FDA accepts supplemental NDA for presbyopia treatment
➤ FDA grants IND to ocular inflammation, pain treatment for potential expanded indication
➤ Enrollment complete in Phase 3 trial evaluating retinitis pigmentosa therapy
➤ ASCRS news and events
➤ First patient treated with novel crosslinking approach for refractive error
➤ Multisociety working group established to set guidelines for modern IOL classification
➤ FDA reduces clinical trial requirement for new drugs to one pivotal trial
➤ ASCRS news and events
➤ Positive results in Phase 3 superiority trial for wet AMD treatment
➤ Dosing begins for first-in-human myopia prevention drop
➤ Pre-NDA meeting with FDA for IOP-lowering drop
➤ Company news
➤ ASCRS news and events
➤ Enrollment complete in Phase 3 trial for wet AMD
➤ Dosing complete in Phase 1/2 trial for retinitis pigmentosa treatment
➤ First patient dosed in gene therapy study for optic nerve disorder
➤ Company news
➤ New drop for temporary presbyopia relief approved
➤ First-in-human results for accommodating IOL
➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy
➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
